Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Genmab A/S (CSE: GEN, Nasdaq: GMAB)

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base includes a number of proprietary next generation antibody technologies Genmab has alliances with other leading pharmaceutical and biotechnology companies. *


Period Start 1999-01-01 established
  Group Genmab (Group)
Products Industry DuoBody technology platform (bispecific antibodies)
  Industry 2 Darzalex®
Persons Person van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
  Person 2 Pagano, Anthony (Genmab 202003– CFO before SVP Finance + CorpDev since 2011 joined 2007)
Region Region København (Copenhagen)
  Country Denmark
  Street 43 Kalvebod Brygge
  City 1560 Copenhagen V
  Tel +45-70-202728
    Address record changed: 2020-12-02
Basic data Employees D: 101 to 500 (2018-12-31)
  Currency DKK
  Annual sales 3,040,539,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 1,472,141,000 (2018-12-31)
  Cash 478,190,000 (2018-12-31)
    * Document for »About Section«: Genmab A/S. (7/12/19). "Press Release: Genmab and Blink Biomedical Enter into Commercial License Agreement". Copenhagen.
Record changed: 2023-07-10


Picture Berlin Partner Voices from HealthCapital Charpentier 650x200px

More documents for Genmab (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Stier Group MIXiii Lifescience Healthtech Conference 650x300px

» top